MBX Biosciences, Inc. - 8-K Filing
MBX Biosciences reports Q3 2026 net loss of $62.4 million and maintains cash runway into 2029 with $481.6 million in liquidity. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $MBX